Literature DB >> 29713823

Higher visceral fat area/subcutaneous fat area ratio measured by computed tomography is associated with recurrence and poor survival in patients with mid and low rectal cancers.

Kang Hong Lee1, Bo-Kyeong Kang2, Byung Kyu Ahn3.   

Abstract

PURPOSE: Obesity is thought to influence postoperative complications and recurrence of mid and low rectal cancer (MLRC) because of intraoperative technical difficulties. However, few reports have described the relationship between obesity indices and the clinical outcomes of MLRC. This study aimed to investigate the association between visceral obesity on computed tomography (CT) and oncolofical outcomes after surgery for MLRC and identify the obesity index that most accurately reflects clinical outcomes.
METHODS: We investigated 125 patients who underwent curative resection for MLRC between 2004 and 2010. Visceral fat area (VFA) was defined as the umbilicus-level intra-abdominal adipose tissue area measured by CT. Body mass index (BMI), total fat area, VFA, subcutaneous fat area (SFA) and VFA/SFA ratio (V/S ratio) were analysed.
RESULTS: The median follow-up time was 60.3 months (range, 38.2-122.6 months). Recurrence was detected in 28 (22.4%) patients. Among the various obesity indices, recurrence was significantly associated with V/S ratio only (1.02 ± 0.45 versus 0.86 ± 0.34; P = 0.046). Stage, preoperative carcinoembryonic antigen level, V/S ratio, lymphatic invasion and perineural invasion were significantly associated with recurrence on univariate analysis, while only V/S ratio (P = 0.019; 95% confidence interval, 1.22 to 9.09) was significantly associated with recurrence on multivariate analysis. Disease-free and overall survival of the obese group (V/S ratio > 1.0) were shorter than those of the non-obese group.
CONCLUSIONS: V/S ratio is the optimal obesity index for predicting stage I-III MLRC recurrence.

Entities:  

Keywords:  Obesity; Rectal cancer; Visceral; Visceral fat area/subcutaneous fat area ratio

Mesh:

Year:  2018        PMID: 29713823     DOI: 10.1007/s00384-018-3065-z

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  12 in total

1.  Abdominal fat: standardized technique for measurement at CT.

Authors:  T Yoshizumi; T Nakamura; M Yamane; A H Islam; M Menju; K Yamasaki; T Arai; K Kotani; T Funahashi; S Yamashita; Y Matsuzawa
Journal:  Radiology       Date:  1999-04       Impact factor: 11.105

2.  Visceral obesity is associated with outcomes of total mesorectal excision for rectal adenocarcinoma.

Authors:  Nikiforos Ballian; Meghan G Lubner; Alejandro Munoz; Bruce A Harms; Charles P Heise; Eugene F Foley; Gregory D Kennedy
Journal:  J Surg Oncol       Date:  2011-07-12       Impact factor: 3.454

3.  Obesity is an independent prognostic variable in colon cancer survivors.

Authors:  Frank A Sinicrope; Nathan R Foster; Daniel J Sargent; Michael J O'Connell; Cathryn Rankin
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

Review 4.  Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome.

Authors:  B L Wajchenberg
Journal:  Endocr Rev       Date:  2000-12       Impact factor: 19.871

5.  Comparison of anthropometric, area- and volume-based assessment of abdominal subcutaneous and visceral adipose tissue volumes using multi-detector computed tomography.

Authors:  P Maurovich-Horvat; J Massaro; C S Fox; F Moselewski; C J O'Donnell; U Hoffmann
Journal:  Int J Obes (Lond)       Date:  2006-09-05       Impact factor: 5.095

Review 6.  Genetic and nongenetic determinants of regional fat distribution.

Authors:  C Bouchard; J P Després; P Mauriège
Journal:  Endocr Rev       Date:  1993-02       Impact factor: 19.871

7.  Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation.

Authors:  Whalen Clark; Erin M Siegel; Y Ann Chen; Xiuhua Zhao; Colin M Parsons; Jonathan M Hernandez; Jill Weber; Shalini Thareja; Junsung Choi; David Shibata
Journal:  J Am Coll Surg       Date:  2013-03-21       Impact factor: 6.113

8.  The impact of visceral obesity on surgical outcomes of laparoscopic surgery for colon cancer.

Authors:  Jun Watanabe; Kenji Tatsumi; Mitsuyoshi Ota; Yusuke Suwa; Shinsuke Suzuki; Akira Watanabe; Atsushi Ishibe; Kazuteru Watanabe; Hirotoshi Akiyama; Yasushi Ichikawa; Satoshi Morita; Itaru Endo
Journal:  Int J Colorectal Dis       Date:  2013-12-03       Impact factor: 2.571

9.  Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

Authors:  Jeffrey A Meyerhardt; Joel E Tepper; Donna Niedzwiecki; Donna R Hollis; A David McCollum; Denise Brady; Michael J O'Connell; Robert J Mayer; Bernard Cummings; Christopher Willett; John S Macdonald; Al B Benson; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2004-02-15       Impact factor: 44.544

10.  Body mass index does not affect postoperative morbidity and oncologic outcomes of total mesorectal excision for rectal adenocarcinoma.

Authors:  Nikiforos Ballian; Brett Yamane; Glen Leverson; Bruce Harms; Charles P Heise; Eugene F Foley; Gregory D Kennedy
Journal:  Ann Surg Oncol       Date:  2010-01-15       Impact factor: 5.344

View more
  8 in total

1.  Can the mesorectal fat tissue volume be used as a predictive factor in foreseeing the response to neoadjuvant chemoradiotherapy in rectum cancer? A CT-based preliminary study.

Authors:  Okan Dilek; Huseyin Akkaya; Cenk Parlatan; Tolga Koseci; Zeynel Abidin Tas; Gökhan Soker; Bozkurt Gulek
Journal:  Abdom Radiol (NY)       Date:  2021-01-26

2.  Combined Effects of Dyslipidemia and High Adiposity on the Estimated Glomerular Filtration Rate in a Middle-Aged Chinese Population.

Authors:  Xichang Wang; Haoyu Wang; Jiashu Li; Xiaotong Gao; Yutong Han; Weiping Teng; Zhongyan Shan; Yaxin Lai
Journal:  Diabetes Metab Syndr Obes       Date:  2021-11-10       Impact factor: 3.168

3.  BMI May Be a Prognostic Factor for Local Advanced Rectal Cancer Patients Treated with Long-Term Neoadjuvant Chemoradiotherapy.

Authors:  Hengchang Liu; Ran Wei; Chunxiang Li; Zhixun Zhao; Xu Guan; Ming Yang; Zheng Liu; Xishan Wang; Zheng Jiang
Journal:  Cancer Manag Res       Date:  2020-10-20       Impact factor: 3.989

4.  Low psoas muscle index is a poor prognostic factor for lower gastrointestinal perforation: a single-center retrospective cohort study.

Authors:  Hajime Kayano; Eiji Nomura; Rin Abe; Yasuhiko Ueda; Takashi Machida; Chikara Fujita; Shohei Uchiyama; Kazuyuki Endo; Katsuki Murakami; Masaya Mukai; Hiroyasu Makuuchi
Journal:  BMC Surg       Date:  2019-11-28       Impact factor: 2.102

5.  Association of subcutaneous and visceral adipose tissue with overall survival in Taiwanese patients with bone metastases - results from a retrospective analysis of consecutively collected data.

Authors:  Wen Ching Chuang; Ngan Ming Tsang; Chi Cheng Chuang; Kai Ping Chang; Ping Ching Pai; Kuan Hung Chen; Wen Chi Chou; Shiao Fwu Tai; Shu Chen Liu; Kin Fong Lei
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

6.  Relationship between BMI, CT-derived body composition and colorectal neoplasia in a bowel screening population.

Authors:  Domenic G Di Rollo; Josh McGovern; Christopher Morton; Gillian Miller; Ross Dolan; Paul G Horgan; Donald C McMillan; David Mansouri
Journal:  Scott Med J       Date:  2022-05-22       Impact factor: 2.426

7.  Obesity may not be related to pathologic response in locally advanced rectal cancer following neoadjuvant chemoradiotherapy.

Authors:  Quoc Riccardo Bao; Filippo Crimì; Giovanni Valotto; Valentina Chiminazzo; Francesca Bergamo; Alessandra Anna Prete; Sara Galuppo; Badr El Khouzai; Emilio Quaia; Salvatore Pucciarelli; Emanuele Damiano Luca Urso
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

8.  Visceral-to-Subcutaneous Fat Ratio Is a Potential Predictor of Postoperative Complications in Colorectal Cancer.

Authors:  An-Qi He; Chun-Qiang Li; Qi Zhang; Tong Liu; Jian Liu; Gang Liu
Journal:  Med Sci Monit       Date:  2021-06-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.